MRNA

Moderna
D

MRNA

Moderna balance sheet 2016–2026

Moderna had 1.20B USD in cash and short-term investments on 30 September 2026, against total debt of 4.18B USD: net debt of 2.98B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
1.20B2.60B1.93B2.91B3.21B6.85B2.62B235.88M658.36M134.86M50.08M
Short-term investments
0.003.20B5.10B5.70B6.70B3.88B1.98B867.12M863.06M621.17M1.01B
1.20B5.80B7.03B8.60B9.90B10.73B4.61B1.10B1.52B756.03M1.06B
Cash growth
-73.47%-17.45%-18.35%-13.11%-7.69%+132.79%+317.77%-27.50%+101.24%-28.55%—
Receivables
1.37B284.00M592.00M1.08B1.69B3.32B1.41B16.30M30.58M18.40M17.95M
Inventory
313.00M153.00M117.00M202.00M949.00M1.44B47.00M0.000.000.000.00
Other current assets
4.47B45.00M58.00M88.00M44.00M26.00M11.00M1.03M595.00K951.00K0.00
Total current assets
7.34B6.54B8.10B10.33B13.43B16.07B6.30B1.13B1.56B783.22M1.09B
Property, plant and equipment
2.72B2.85B2.96B2.66B2.14B1.38B387.00M287.91M211.98M139.03M81.21M
Long-term investments
2.81B2.34B2.51B4.74B8.36B6.84B639.00M159.99M172.99M145.85M236.57M
Goodwill and intangibles
—97.00M92.00M96.00M———————
Goodwill
—52.00M52.00M52.00M———————
Intangible assets
—45.00M40.00M44.00M———————
Other non-current assets
596.00M421.00M407.00M523.00M946.00M46.00M13.00M12.72M14.18M16.38M12.23M
Total assets
13.47B12.34B14.14B18.43B25.86B24.67B7.34B1.59B1.96B1.08B1.42B
Accounts payable
259.00M317.00M405.00M520.00M487.00M302.00M18.00M7.09M31.21M20.73M28.16M
Deferred revenue
268.00M99.00M153.00M568.00M2.04B6.25B3.87B63.31M109.06M96.74M107.74M
Short-term debt
0.000.000.000.000.000.000.000.000.000.000.00
Other current liabilities
1.76B1.57B863.00M842.00M243.00M140.00M99.00M32.49M26.87M19.50M13.54M
Total current liabilities
2.03B1.99B2.21B3.02B4.92B9.13B4.39B143.12M222.80M191.46M162.80M
Long-term debt
4.18B1.24B0.000.000.000.000.000.000.000.000.00
Other non-current liabilities
424.00M-368.00M267.00M256.00M135.00M76.00M3.00M138.00K10.26M9.12M5.76M
Lease obligations, current
0.000.0037.00M25.00M196.00M211.00M30.00M0.000.000.000.00
Lease obligations, long-term
0.00673.00M710.00M1.22B1.00B705.00M207.00M132.36M33.49M15.69M12.50M
Total liabilities
6.63B3.69B3.24B4.57B6.74B10.52B4.78B414.61M431.91M459.19M575.31M
Common stock and paid-in capital
0.000.000.000.000.000.000.0034.00K33.00K6.00K6.00K
Retained earnings
5.26B7.22B10.05B13.61B18.32B9.96B-2.24B-1.50B-1.01B-621.89M-365.72M
Accumulated other comprehensive income
8.00M45.00M-10.00M-123.00M-370.00M-24.00M3.00M1.80M-1.32M-1.16M-403.00K
Shareholders' equity
6.84B8.65B10.90B13.85B19.12B14.15B2.56B1.17B1.53B625.30M841.85M
Minority interest
0.000.000.000.000.000.000.000.000.000.000.00
4.18B1.90B747.00M1.24B1.20B916.00M237.00M132.36M33.49M15.69M12.50M
Net cash
-2.98B3.90B6.28B7.36B8.70B9.81B4.37B970.64M1.49B740.34M1.05B
Working capital
5.32B4.56B5.89B7.31B8.51B6.94B1.91B985.69M1.34B591.76M924.35M
Book value per share
15.9022.2428.3936.2745.9732.826.723.554.651.6613.13
Tangible book value
6.84B8.55B10.81B13.76B19.12B14.15B2.56B1.17B1.53B625.30M841.85M
Tangible book value per share
15.9021.9928.1536.0245.9732.826.723.554.651.6613.13
Current ratio
3.623.293.673.422.731.761.447.897.024.096.68
Debt to equity
0.610.220.070.090.060.060.090.110.020.030.01

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Moderna's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.